Portfoliotracker

Crescent Biopharma, Inc.

CBIO · NASDAQCM · Healthcare Biotechnology 22/100 E

13,50 $
▼ −0,65 (−4,59 %)
Pre-market delayed by 15 min
Price as of 16. 11. 22:00, fetched 17. 11. 13:29
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score22 / 100 Market cap412 mil. $ P/E– Forward P/E-5,0 P/S27,5 P/B1,5 EV/EBITDA– Dividend yield– FCF yield-20,00 % EPS-7,63 $ Net margin0,0 % Return on equity– Beta– Debt / equity0,01
52-week range 8,72 to 27,41
3-month average volume0,4 M

Finance

Where the revenue goes

Loading the income statement flow…

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.

Employees
80
Country
United States
Fiscal year end
31. 12.
Data since
10. 1. 2014

Explore further

Similar companies BNTC

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account